LEADER 01015nam0 22002531i 450 001 UON00390351 005 20231205104608.961 100 $a20110324d1962 |0itac50 ba 101 $apor 102 $aBR 105 $a|||| ||||| 200 1 $aEnsaio sobre a musica brasileira$fMario de Andrade 210 $aSao Paulo$cLivraria Martins Editora$d1962 215 $a188 p.$d22 cm. 410 1$1001UON00390336$12001 $aObras Completas de Mario de Andrade$fSao Paulo$eLivraria Martins Editora.$vVI 620 $aBR$dSão Paulo$3UONL002145 700 1$aANDRADE$bMário : de$3UONV120652$070736 712 $aLivraria Martins Editora$3UONV277871$4650 801 $aIT$bSOL$c20240220$gRICA 899 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$2UONSI 912 $aUON00390351 950 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$dSI Bras XI 0048 $eSI PO 5142 7 0048 996 $aEnsaio sobre a musica brasileira$91354804 997 $aUNIOR LEADER 04098nam 2201189z- 450 001 9910566469403321 005 20220506 035 $a(CKB)5680000000037686 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/81005 035 $a(oapen)doab81005 035 $a(EXLCZ)995680000000037686 100 $a20202205d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aDiagnosis, Treatment and Prevention of Age-Related Macular Degeneration 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 online resource (246 p.) 311 08$a3-0365-3930-1 311 08$a3-0365-3929-8 330 $aIn this reprint, we hope to review the basics and highlight the latest developments in AMD. This demonstrates the benefits of the international scientific community working on this disease, to limit its negative impacts, the most vital of which is the loss of visual function, leading to a loss of autonomy and a decrease in patients' quality of life. 606 $aMedicine and Nursing$2bicssc 610 $aaflibercept 610 $aaflibercept monotherapy 610 $aage-related macular degeneration 610 $aage-related macular degeneration (AMD) 610 $aAMD 610 $aangiogenesis 610 $aanti-vascular endothelial growth factor 610 $aanti-vascular endothelial growth factor 610 $aanti-VEGF 610 $aanti-VEGF treatment 610 $aAREDS2-HOME study 610 $aarterial hypertension 610 $abevacizumab 610 $abrolucizumab 610 $acardiovascular risk factors 610 $acataract surgery 610 $achoriocapillaris 610 $achoroidal neovascularisation 610 $achoroidal neovascularization 610 $aclinical trials 610 $acomparative therapies 610 $aDelphi 610 $adisease activity 610 $aeffectiveness 610 $aemerging treatment 610 $aepithelial tear 610 $aexudation 610 $afellow eye 610 $afood supplement 610 $aForeseeHome AMD Monitoring System® 610 $agood baseline visual acuity 610 $ahereditary retinal dystrophy 610 $aidentification 610 $aintravitreal anti-vascular endothelial growth factor 610 $alifestyle 610 $along-term FU 610 $amacula-off rhegmatogenous detachment 610 $amacular neovascularization 610 $ameta-analysis 610 $ameta-regression 610 $ameteorin 610 $an/a 610 $aneovascular age-related macular degeneration 610 $aneovascular age-related macular degeneration (nAMD) 610 $anutrients 610 $aoct-angiography 610 $aoptical coherence tomography 610 $aoptical coherence tomography angiography 610 $apolypoidal choroidal vasculopathy 610 $aprevention 610 $apro re nata regimen 610 $aquiescent macular neovascularization 610 $aranibizumab 610 $areading acuity 610 $areal-world evidence 610 $aretina 610 $aretinal deep perifoveal capillary plexus 610 $arisk 610 $aSorsby 610 $aSorsby's fundus dystrophy 610 $aSTARS® 610 $asuperficial perifoveal capillary plexus 610 $aswitch therapy 610 $atherapeutic innovation 610 $atreat and extend 610 $atreat-and-extend 610 $atreatment change 610 $atreatment outcome 610 $atreatment-naive 610 $aVascular Endothelial Growth Factor (VEGF) 610 $avisual acuity 615 7$aMedicine and Nursing 700 $aKodjikian$b Laurent$4edt$01326251 702 $aKodjikian$b Laurent$4oth 906 $aBOOK 912 $a9910566469403321 996 $aDiagnosis, Treatment and Prevention of Age-Related Macular Degeneration$93037217 997 $aUNINA